Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Merck Wants to Extend RSV Vaccine to Second Season

3 September 2026 · By · Wire by Fusion42

Published

3 September 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at respiratory-therapy.com →

◆ Verified

Fusion42 · 3 September 2026 · Fusion42 review

The FDA and EMA are reviewing Merck's supplemental application to extend the use of its Enflonsia RSV vaccine to protect high-risk children under 2 years during their second RSV season, supported by phase 3 SMART trial data.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You face a new opportunity to offer extended protection for vulnerable children with chronic lung or heart conditions by integrating Merck’s impending second-season RSV vaccine approval into your product roadmap.

◆ Coverage

1 source · 3 Sep 2026

◆ Related on Wire

◆ Topics

Healthrsvvaccinepediatricsregulatory-approvalmerck